Team

Management

Jon Edelson, MD

Founder, Chairman, CEO and President
Dr. Edelson has more than 20 years of experience starting and running health care companies as CEO, including Advanced Health, which he co-founded and led through initial and secondary public stock offerings. As CEO, Dr. Edelson previously also co-founded venture-backed Aureon Biosciences and Physicians’ Online, the latter of which was acquired for approximately $180 million. Prior, as CEO, Dr. Edelson founded Medical Decision Resources, which was acquired by prescription benefit manager ValueRx. From January to August, 2014, Dr. Edelson was a board member for Covagen, AG, a Swiss biopharmaceutical that was acquired by Johnson & Johnson. Dr. Edelson has been awarded patents for his inventions and is a co-inventor of ANT-1207 and AI-09. Dr. Edelson has been the lead author for articles published in peer-reviewed medical journals such as the Journal of the American Medical Association. Dr. Edelson received a BA (summa cum laude) from Yale University and an MD (with honors) from the University of Chicago. Dr. Edelson attended the Harvard School of Public Health and was a Dana Scholar at the University of Pennsylvania School of Medicine. Dr. Edelson was Board Certified in Internal Medicine after completing his training at Harvard’s Brigham & Women’s Hospital.

Fabian Tenenbaum, MBA

Chief Financial Officer, Chief Business Officer
Immediately prior to joining Anterios, Mr. Tenenbaum was CEO of Iluminage Beauty, a Unilever joint-venture company that develops energy-based aesthetic medical devices for consumer use. From 2011 to 2013, he co-founded and then served as CEO of Syneron Beauty until the company was spun-off to Unilever. From 2007 to 2011, Mr. Tenenbaum was Executive Vice President and CFO for Syneron-Candela (NASDAQ: ELOS), a leading global aesthetic medical device company, where he oversaw financial management and investor relations, M&A strategy, global commercial initiatives and partnerships. Prior to Syneron, he held executive leadership positions with several life-science companies including Radiancy and Sunlight Medical. Mr. Tenenbaum holds an MBA (as a Dean’s List honoree) from Columbia University and a Bachelor in Medicine (summa cum laude) from the Faculty of Medicine at Ben Gurion University. He has served on the Board of Directors for Rakuto Bio Technologies Ltd. and Fluorinex Active Ltd.

Klaus Theobald, MD, PhD

Chief Research & Development Officer
Dr. Theobald, immediately prior to joining Anterios, led research and development at CollaGenex, a publicly traded US pharmaceutical company, where he developed prescription dermatology products, including Oracea® and Mirvaso®, which are currently both on the market and being sold by Galderma after it acquired CollaGenex for approximately $420 million in 2008. Dr. Theobald has more than 25 years of bio-pharmaceutical development experience developing dozens of biologic and small molecule products. He previously served as Vice President R&D and Chief Medical Officer in the U.S. for Aventis Behring, and Senior Director, Worldwide Corporate Project Management and Head of Clinical Research Immunology for Behringwerke. Dr. Theobald holds a MD and PhD (magna cum laude) from Johannes Gutenberg University in Germany.

Mary Senica

Vice President for Quality Assurance and Compliance
Ms. Senica supervises our outsourced manufacturing and testing activities, as well as our Select Agent licensure program, where she serves in the capacity of Responsible Official. She has more than 20 years experience in the biomedical field, including at such firms as Ipsen, Armstrong Pharmaceuticals, Acambis, and Genzyme. Ms. Senica holds a MS from the University of Georgia and a BS from the University of Notre Dame.

Directors

Jon Edelson, MD

Dr. Edelson, Anterios’s founder, Chairman, CEO and President, has more than 20 years of experience starting and running health care companies as CEO, including Advanced Health, which he co-founded and led through initial and secondary public stock offerings. As CEO, Dr. Edelson previously also co-founded venture-backed Aureon Biosciences and Physicians’ Online, the latter of which was acquired for approximately $180 million. Prior, as CEO, Dr. Edelson founded Medical Decision Resources, which was acquired by prescription benefit manager ValueRx. From January to August 2014, he was a board member for Covagen, AG, a Swiss biopharmaceutical that was acquired by Johnson & Johnson. Dr. Edelson has been awarded patents for his inventions and is a co-inventor of ANT-1207 and AI-09. Dr. Edelson has been the lead author for articles published in peer-reviewed medical journals such as the Journal of the American Medical Association. Dr. Edelson received a BA (summa cum laude) from Yale University and an MD (with honors) from the University of Chicago. Dr. Edelson attended the Harvard School of Public Health and was a Dana Scholar at the University of Pennsylvania School of Medicine. Dr. Edelson was Board Certified in Internal Medicine after completing his training at Harvard’s Brigham & Women’s Hospital.

Carter Meyer

Mr. Meyer has served as a member of our Board of Directors since January 2007. Since February 2006, Mr. Meyer has been the Chief Executive Officer of SHD GP, LLC, which is the general partner of Scientific Health Development, Ltd. (“SHD”), a life sciences investment fund. Prior to joining SHD, he was an attorney in private practice for more than 12 years, most recently with Vinson & Elkins LLP, focusing on commercial transactions, with substantial experience buying, selling, financing and investing in both public and private entities. Mr. Meyer has a BBA in finance from Texas Christian University and a JD from St. Mary’s University School of Law.

Geoffrey Smith

Mr. Smith has served as a member of our Board of Directors since December 2006. He is a co-founder and has been a General Partner of Ascent Biomedical Ventures, a venture capital firm focused on early-stage life sciences investments. He is also the founding Director of the Mount Sinai Institute of Technology at the Icahn School of Medicine at Mount Sinai (“ISMMS”), which he founded in December 2013, and has been a professor in the Department of Population Health Science and Policy at ISMMS since July 2012. In addition, Mr. Smith has been a Visiting Scholar at Rockefeller University since October 2007, where he founded and directs the University’s Science & Economics Program, and has been an adjunct faculty member at the RU Center for Clinical and Translational Science since September 2009. Mr. Smith received a BA (with honors) from Williams College and a JD from the University of Pennsylvania Law School.